Urteste publishes first peer-reviewed paper on Panuri cancer test

Urteste said July 22, 2026, that Diagnostics has published the first peer-reviewed paper on the analytical validation of Panuri, its urine-based pancreatic cancer test. The publication comes as the Polish biotech advances a multicenter European clinical study and prepares to present the program at ADLM 2026 in Anaheim.

Why it matters: - Urteste’s first peer-reviewed Panuri paper gives outside scientific validation to a test the company is advancing for earlier pancreatic cancer detection. - Pancreatic cancer is often diagnosed late, so a non-invasive urine test could affect how patients enter the diagnostic pathway. - The publication may also help Urteste as it works through clinical and regulatory steps for Panuri in Europe.

What happened: - Urteste S.A. said July 22, 2026, that Diagnostics published a peer-reviewed article on the analytical validation of Panuri, the company’s investigational urine-based test for pancreatic cancer. - The paper is titled “Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer.” - The company said the article marks a milestone for Panuri development. - Urteste said the article is available in Diagnostics (2026): the published paper.

The details: - Panuri is an investigational in vitro diagnostic device and has not yet obtained CE marking. - The test is undergoing a multicenter clinical performance evaluation across Europe under the In Vitro Diagnostic Medical Devices Regulation. - Panuri is being developed to support diagnosis of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. - The technology measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - Urteste said the analytical development of the Panuri assay showed 89% analytical sensitivity, with a 95% confidence interval of 78.5% to 94.9%. - Urteste said the assay showed 75% analytical specificity, with a 95% confidence interval of 64.8% to 83.5%. - Urteste said the assay demonstrated high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility. - The company said coefficients of variation were below 10%. - Urteste said the new paper provides the scientific description of the analytical results and validation work completed during development. - The company is currently running a prospective multicenter clinical performance study in patients being evaluated for suspected pancreatic cancer. - The study spans 30 clinical sites in Poland, Italy and Hungary. - The study is expected to include about 550 evaluable participants. - Urteste said the results will support the European regulatory process for Panuri as an IVD test under IVDR. - Urteste currently has 13 prototypes of diagnostic tests covering cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - The company said those cancers together account for nearly 70% of cancer-related deaths worldwide. - Urteste’s platform detects cancers by measuring enzyme activity in urine and using tests that change urine color intensity.

Between the lines: - The peer-reviewed publication helps shift Panuri from a development story to a test with public scientific documentation behind it. - The move also suggests Urteste is trying to build credibility with regulators, researchers and potential commercial partners before broader market entry. - The combination of a publication, an active clinical study and a major industry conference points to a marketing and validation push at the same time.

What’s next: - Urteste said members of its management board will attend ADLM 2026 in Anaheim, California, from July 26–30, 2026. - The company plans to present progress on Panuri, discuss the publication and the ongoing clinical study, and meet potential strategic and commercial partners. - Urteste said it will continue the international clinical study as part of the regulatory path for Panuri.

The bottom line: - Urteste now has peer-reviewed analytical data in hand for Panuri, but the test still needs clinical results and regulatory clearance before any broader use.